Skip to Content
Also part of the UPMC family:
Monoclonal Antibodies Provider Banner
Monoclonal Antibodies Provider Mobile

Monoclonal Antibody Administration

For Providers: Ordering Monoclonal Antibody Administration for Patients 

If you are a non-UPMC provider and would like to order the Monoclonal Antibody administration for a patient under your care, please:

NOTE: UPMC will no longer accept any prior referral sources.

Eligible patients are typically contacted within 24 to 48 hours if an appointment time is available.

If you are a patient and want information about Monoclonal Antibody treatment, call 866-804-5251.

COVID-19 Treatment: Monoclonal Antibody Administration

UPMC is one of the few health care organizations in Pennsylvania offering monoclonal antibody treatment, which is authorized by the FDA for emergency use in the treatment of COVID-19.

This one-time administration may help keep certain individuals with mild to moderate COVID-19 from progressing in their illness to severe disease and may make it less likely that a patient would need to go to the emergency department or need hospitalization.

UPMC is using a monoclonal antibody administration treatment product in outpatient infusion center locations throughout western, central, and north central PA. The product is:

Fact Sheet for Health Care Providers: EUA for Bebtelovimab (fda.gov)

Fact Sheet for Patients, Parents, and Caregivers: EUA of Bebtelovimab for Coronavirus Disease 2019 (COVID-19) (fda.gov)

UPMC can administer available monoclonal antibody treatments for COVID-19 positive patients who meet specific criteria and for whom the antibodies may be an effective treatment. 

Monoclonal Antibody Administration: Indications for Use

IMPORTANT!

  • Patient must still be symptomatic and within the established timeframe
  • If symptoms have resolved or if the patient now requires new or escalating oxygen therapy, do not refer the patient for treatment

Eligibility criteria are currently prioritized for the following patients:

  • Test positive for COVID-19 (PCR or antigen test), AND:
  • Have had mild-moderate symptoms for 7 days or less (must still be symptomatic), AND:
  • Not have a new or increased O2 requirement, AND:
  • One of the following medical conditions:
    • Ineligible for Paxlovid (days 6 to 7 of symptoms, eGFR < 30, or drug interaction)
    • Age 65 years or older
    • CD4 count less than 200 or less than 15%
    • Chimeric antigen receptor (CAR-T) therapy within past 2 years
    • Graft-versus-host disease
    • Hematological malignancy
    • Hematopoietic cell transplant
    • Pregnancy
    • Receiving alemtuzumab, fludarabine, cladribine, ibritumomab, rituximab, ocrelizumab, ofatumumab, ibrutinib, acalabrutinib, fingolimod, Siponimod, ozanimod, ponesimod therapy
    • Solid organ transplant
    • Severe primary immunodeficiency

Monoclonal Antibody Administration: Limitations of Use

Not authorized for use in patients:

  • Who are hospitalized due to COVID-19
  • Who require oxygen therapy due to COVID-19
  • Who require an increase in baseline oxygen flow rate due to COVID-19

Monoclonal antibodies, such as casirivimab and imdevimab, may be associated with worse clinical outcomes when administered to hospitalized patients requiring high flow oxygen or mechanical ventilation with COVID-19.

Monoclonal Antibody Administration: Considerations

With many medications, there is a risk of allergic reaction, albeit reactions to these medications requiring discontinuation are very rare. The infusion centers have trained staff and appropriate medications to address any reaction, including: fever, chills, nausea, headache, shortness of breath, low blood pressure, wheezing, swelling of lips, face, or throat, rash including hives, itching, muscle aches, and dizziness.

COVID-19 Vaccines and Monoclonal Antibody Administration

Persons who have received a COVID-19 vaccine may receive monoclonal antibody at any point after the vaccination, if the person is eligible to receive monoclonal antibody.

Persons who received monoclonal antibodies for treatment of COVID-19 can receive a COVID-19 vaccine as soon as they are clinically well (recovered) and considered no longer contagious.

Learn more about Infection Prevention and Control criteria applied to determine duration of precautions (PDF).

Information for Patients

Check out our web page for information for patients about Paxlovid™ and monoclonal antibody treatment.

Information about Monoclonal Antibody Pre-Exposure Prophylaxis for Immunocompromised Patients

Evusheld is a potent new COVID-19 protective measure (monoclonal antibody) designed to prevent COVID-19 infection in vulnerable and immunocompromised individuals.

Learn more about this medication.